Scynexis (SCYX) Non-Current Assets (2013 - 2026)
Scynexis' (SCYX) quarterly Non-Current Assets came in at $14.9 million in Q1 2026, down 4.84% YoY from $15.7 million in Q1 2025, and down 19.93% on a QoQ basis from $18.7 million in Q4 2025.
Scynexis (SCYX) Non-Current Assets (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Non-Current Assets data on file, last reported at $14.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 4.84% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.2 million (down 39.11% YoY) and the FY2025 annual result came in at $18.7 million, up 1.03% from the prior year.
- Non-Current Assets retreated to $14.9 million in Q1 2026, from $18.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $26.3 million in Q4 2023 to a low of $2.4 million in Q3 2025.
- A 5-year average of $13.3 million and a median of $13.2 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets jumped 200.56% — and 2025, when it tumbled 87.2%.
- Tracing SCYX's Non-Current Assets over 5 years: stood at $8.7 million in 2022, then jumped by 200.56% to $26.3 million in 2023, then declined by 29.79% to $18.5 million in 2024, then climbed by 1.03% to $18.7 million in 2025, then retreated by 19.93% to $14.9 million in 2026.
- The last three Non-Current Assets figures came in at $14.9 million (Q1 2026), $18.7 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.11 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.27 Bn | 39.61 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.81 Bn | 30.14 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 2.96 Bn |
| 10 | Scynexis | 61.60 Mn | -53.09 Mn | - | 18.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.73 Mn |
| Mar 31, 2026 | 14.94 Mn |
| Dec 31, 2025 | 18.65 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 4.20 Mn |
| Mar 31, 2025 | 15.69 Mn |
| Dec 31, 2024 | 18.46 Mn |
| Sep 30, 2024 | 18.58 Mn |
| Jun 30, 2024 | 13.23 Mn |
| Mar 31, 2024 | 16.58 Mn |
| Dec 31, 2023 | 26.30 Mn |
| Sep 30, 2023 | 19.91 Mn |
| Jun 30, 2023 | 9.33 Mn |
| Mar 31, 2023 | 10.53 Mn |
| Dec 31, 2022 | 8.75 Mn |
| Sep 30, 2022 | 8.73 Mn |
| Jun 30, 2022 | 9.94 Mn |
| Mar 31, 2022 | 9.66 Mn |
| Dec 31, 2021 | 10.46 Mn |
| Sep 30, 2021 | 5.95 Mn |